{
  "source": "PA-Notification-Cimzia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1017-15\nProgram Prior Authorization/Notification\nMedication Cimzia® (certolizumab)\nP&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,\n11/2011, 7/2012, 11/2012, 11/2013, 2/2015, 3/2016, 3/2017, 3/2018,\n9/2018, 5/2019, 9/2019, 9/2020, 9/2021, 9/2022, 7/2023, 10/2024,\n11/2024\nEffective Date 2/1/2025\n1. Background:\nCimzia (certolizumab) is a tumor necrosis factor (TNF) blocker indicated for reducing signs\nand symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients\nwith moderately to severely active disease who have had an inadequate response to\nconventional therapy. Cimzia is also indicated for the treatment of adults with moderately to\nseverely active rheumatoid arthritis (RA), treatment of adult patients with active psoriatic\narthritis (PsA), treatment of adults with active ankylosing spondylitis (SpA), treatment of\nadults with moderate to severe plaque psoriasis (PS) who are candidates for systemic therapy\nor phototherapy, for the treatment of adults with non-radiographic axial spondyloarthritis (nr-\naxSpA), with objective signs of inflammation, and for the treatment of active polyarticular\njuvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.\n2. Coverage Criteriaa:\nA. Crohn’s Disease (CD)\n1. Initial Authorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) Patient has had an inadequate response to conventional therapies (examples\ninclude anti-inflammatory drugs, corticosteroids, or oral immunosuppressive\nagents)\n-AND-\n(3) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\nAuthorization wi",
    "etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\nAuthorization will be issued for 12 months.\nB. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nC. Psoriatic Arthritis (PsA)\n1. Initial Authorization\n© 2024 UnitedHealthcare Services, Inc.\n2\na. Cimzia will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel",
    "proved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab),\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab),\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nD. Ankylosing Spondylitis (AS) and Non-radiographic Axial Spondyloarthritis (nr-\naxSpA)\n1. Initial Authorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis or non-radiographic axial\nspondyloarthritis\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n3\n2. Reauthorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Oren",
    "ion of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nE. Plaque Psoriasis (PS)\n1. Initial Authorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n4\nF. Polyarticular Juvenile Idiopathic Arthritis (pJIA)\n1. Initial Authorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Diagnosis active polyarticular juvenile idiopathic arthritis\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Simponi",
    "gnosis active polyarticular juvenile idiopathic arthritis\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cimzia [package insert]. Smyrna, GA: UCB, Inc; September 2024.\n© 2024 UnitedHealthcare Services, Inc.\n5\nProgram Prior Authorization/Notification - Cimzia (certolizumab)\nChange Control\n11/2013 Background updated. New criteria for psoriatic arthritis and ankylosing\nspondylitis. Concomitant therapy criterion condensed to list four biologic\nDMARDs and revised to include Xeljanz. Reauthorization criteria revised\nto standard verbiage and to include concomitant therapy criterion.\nExtended reauthorization duration to 24 months.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual revie",
    "and to include concomitant therapy criterion.\nExtended reauthorization duration to 24 months.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated background and references.\n3/2016 Annual review. Added Otezla (apremilast) to the combination criteria for\nPsoriatic Arthritis. Updated references.\n3/2017 Annual review with no change to coverage criteria. Updated references.\n3/2018 Annual review with no change to coverage criteria.\n9/2018 Added coverage for plaque psoriasis. Updated background and\nreferences.\n5/2019 Addition of non-radiographic axial spondyloarthritis diagnosis. Updated\nbackground and reference.\n9/2019 Annual review. Updated reference.\n9/2020 Annual review. Changed reauthorization durations to 12 months. Updated\nreference.\n9/2021 Annual review with no change to coverage criteria.\n9/2022 Annual review. Updated JAK inhibitor and biologic DMARD examples\nwith no change to coverage criteria. Added state mandate footnote.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review with no change to coverage criteria.\n11/2024 Added coverage criteria for pJIA. Updated background and reference.\n© 2024 UnitedHealthcare Services, Inc.\n6"
  ]
}